A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.
Status:
Recruiting
Trial end date:
2022-02-20
Target enrollment:
Participant gender:
Summary
Phase 1, single -centre study in 2 parts. The study designs for each part are well
established for first-in-human studies and are appropriate to assess safety, tolerability and
preliminary pharmacokinetics.
Phase:
Phase 1
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborators:
Nucleus Network Ltd Southern Star Research Pty Ltd.